Table 3.
The top 10 cited articles
| Rank | Title | Year, Journal | First author | Total citations | TC per year |
|---|---|---|---|---|---|
| 1 | Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology | 2021, Journal of The National Comprehensive Cancer Network | Deborah K Armstrong | 467 | 93.40 |
| 2 | Targeting DNA damage response pathways in cancer | 2023, Nature Reviews Cancer | Florian J Groelly | 395 | 131.67 |
| 3 | Understanding and overcoming resistance to PARP inhibitors in cancer therapy | 2021, Nature Reviews Clinical Oncology | Mariana Paes Dias | 309 | 61.80 |
| 4 | Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial | 2021, Lancet Oncology | Andrés Poveda | 298 | 59.60 |
| 5 | Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial | 2023, Journal of Clinical Oncology | Paul DiSilvestro | 257 | 85.67 |
| 6 | Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial | 2021, Lancet Oncology | Susana Banerjee | 242 | 48.40 |
| 7 | PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancer | 2021, Redox Biology | Ting Hong | 236 | 47.20 |
| 8 | Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment | 2021, Obstetrics And Gynecology | Katherine C Kurnit | 209 | 41.80 |
| 9 | Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database | 2021, Lancet Haematology | Pierre-Marie Morice | 179 | 35.80 |
| 10 | Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study | 2023, Journal of Clinical Oncology | Ursula A Matulonis | 179 | 59.67 |
TC per Year: Total citations received per year